EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PCSK9 Enhances Cardiac Fibrogenesis via the Activation of Toll-like Receptor and NLRP3 Inflammasome Signaling

Cheng-Chih Chung iD, Yu-Hsun Kao iD, Yao-Chang Chen, Yung-Kuo Lin, Satoshi Higa iD, Kai-Cheng Hsu iD, Yi-Jen Chen iD

International Journal of Molecular Sciences · 23.02.2025 · 26 (5) · 1921

DOI: 10.3390/ijms26051921 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.02.2025. Verfasst von Cheng-Chih Chung und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Proprotein Convertase 9, Inflammasomes, Myocardium. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wan Fang Hospital, Ministry of Science and Technology of Taiwan, Taipei Medical University—Wan Fang Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel target for reducing low-density lipoprotein cholesterol. PCSK9 activates the atherosclerosis process through pro-inflammation signaling. Furthermore, the serum level of PCSK9 is positively correlated with mortality in patients with heart failure (HF). Cardiac fibrosis plays a crucial role in the pathophysiology of HF. In this study, we intended to examine whether PCSK9 can increase fibroblast activities and explore what its underlying mechanisms are. Migration, proliferation analyses, and Western blotting were used on human cardiac fibroblasts with and without PCSK9. Alirocumab (a PCSK9 inhibitor, 10 mg/kg/week intra-peritoneally for 28 consecutive days) was treated in isoproterenol (100 mg/kg, subcutaneous injection)-induced HF rats. PCSK9 (50, 100 ng/mL) increased proliferation, myofibroblast differentiation capability, and collagen type I production. Compared with control cells, PCSK9 (100 ng/mL)-treated cardiac fibroblasts showed higher nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3), interleukin (IL)-1, myofibroblast differentiation, and collagen production capabilities, which were attenuated by MCC950 (an NLRP3 inhibitor, 100 μmol/L). PCSK9 upregulated Myd88 and NF-κB signaling, which were reduced by TAK242 (a toll-like receptor (TLR) 4 inhibitor, 10 μmol/L). Moreover, alirocumab significantly improved left ventricular systolic function and attenuated fibrosis in HF rats. In conclusion, PCSK9 upregulates NLRP3 signaling and the profibrotic activities of cardiac fibroblasts through the activation of TLR4/Myd88/NF-κB signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinProprotein Convertase 9InflammasomesMyocardiumHeart FailureToll-Like ReceptorsAnimalsSignal TransductionRatsHumansFibrosisMaleFibroblastsCell ProliferationRats, Sprague-DawleyNF-kappa BMyeloid Differentiation Factor 88Antibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

NLRP3PCSK9fibroblastsfibrosisinflammasometoll-like receptor

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinProprotein Convertase 9InflammasomesToll-Like ReceptorsPCSK9 protein, ratNF-kappa BMyeloid Differentiation Factor 88Nlrp3 protein, ratalirocumabPCSK9 protein, human

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
  • Division of Cardiovascular Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan.
  • Taipei Heart Institute, Taipei Medical University, Taipei 110, Taiwan.
  • Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
  • Department of Medical Education and Research, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan.
  • Department of Biomedical Engineering, National Defense Medical Center, Taipei 11490, Taiwan.

ORCID-Profile: Cheng-Chih Chung, Yu-Hsun Kao, Satoshi Higa, Kai-Cheng Hsu, Yi-Jen Chen

Förderung

  • Wan Fang Hospital
  • Ministry of Science and Technology of Taiwan
  • Taipei Medical University—Wan Fang Hospital
  • Foundation for the Development of Internal Medicine in Okinawa

Zitieren

APA

Chung, C. C., Kao, Y. H., Chen, Y. C., Lin, Y. K., Higa, S., Hsu, K. C., & Chen, Y. J. (2025). PCSK9 Enhances Cardiac Fibrogenesis via the Activation of Toll-like Receptor and NLRP3 Inflammasome Signaling. International Journal of Molecular Sciences, 26(5), 1921. https://doi.org/10.3390/ijms26051921

Vancouver

Chung CC, Kao YH, Chen YC, Lin YK, Higa S, Hsu KC, et al. PCSK9 Enhances Cardiac Fibrogenesis via the Activation of Toll-like Receptor and NLRP3 Inflammasome Signaling. International Journal of Molecular Sciences. 2025;26(5):1921. doi:10.3390/ijms26051921

BibTeX
@article{Chung2025,
  author = {Chung, Cheng-Chih and Kao, Yu-Hsun and Chen, Yao-Chang and Lin, Yung-Kuo and Higa, Satoshi and Hsu, Kai-Cheng and Chen, Yi-Jen},
  title = {PCSK9 Enhances Cardiac Fibrogenesis via the Activation of Toll-like Receptor and NLRP3 Inflammasome Signaling},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {5},
  pages = {1921},
  doi = {10.3390/ijms26051921}
}
Kostenlos starten →